Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 (canakinumab) for abdominal aortic aneurysm
2013-002088-25Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in abdominal aortic aneurysm (AAA) comparing ACZ885 (canakinumab) arm with Placebo arm (2 arms). Primary endpoint: Primary: Change in AAA size and growth rate at 12 months. Started Sep 2013; status: terminated.
02
Drugs
canakinumab
03
Conditions
abdominal aortic aneurysm (AAA)
Beyond the preview
Go deeper on 2013-002088-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002088-25.